Diplopia and Quality of Life in Patients with Baerveldt 250 Compared to Ahmed FP7 Glaucoma Drainage Devices

Overview

About this study

The purpose of our prospective study is to compare the prevalence of diplopia following 250 Baerveldt and FP7 Ahmed, and to characterize the specific types, causes, and effect of diplopia in these two groups.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Adult surgical glaucoma patients who will be receiving either 250 Baerveldt or FP7 Ahmed
Patients with previous cataract and/or failed trabeculectomy surgery, selective laser trabeculoplasty, trabectome, iStent will be included

Exclusion Criteria:

Patients with multiple GDD, patients with GDD in quadrants other than superior temporal location, and patients with previous scleral buckle will be excluded.
Patients will not be recruited if they cannot read or understand English or if they have severe cognitive impairment prohibiting completion of surveys.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Cheryl Khanna, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Cheryl Khanna, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials